Skerjanec Simona 4
4 · Avidity Biosciences, Inc. · Filed Feb 27, 2026
Research Summary
AI-generated summary of this filing
Avidity (RNAM) Director Simona Skerjanec Sells 59,034 Shares
What Happened
Simona Skerjanec, a director of Avidity Biosciences (RNAM), disposed of a total of 59,034 securities on 2026-02-27. The Form 4 lists three dispositions: 6,692 shares of common stock and two derivative dispositions of 10,034 and 42,308 units. These dispositions were made pursuant to the Agreement and Plan of Merger with Novartis; the merger consideration is $72.00 per share. Options referenced in the filing were cashed out per the merger terms (see Key Details).
Key Details
- Transaction date: 2026-02-27 (reported on Form 4 filed 2026-02-27). Filing appears timely.
- Reported counts: 6,692 common shares; 10,034 and 42,308 derivative dispositions (total 59,034). Form 4 lists prices as N/A because shares/options were disposed to the issuer under the Merger Agreement.
- Merger price: $72.00 per share (per footnotes). Implied gross consideration at $72/share ≈ $4,250,448, though option payouts equal the excess of $72 over each option’s exercise price (so actual cash received for options may differ).
- Shares owned after transaction: Not disclosed in this filing.
- Footnotes:
- F1: Common stock (including RSUs previously reported) disposed pursuant to the Merger Agreement.
- F2: Options were cashed out under the Merger Agreement for a cash payment equal to the excess of the $72 merger consideration over the exercise price.
- Filing timeliness: No late filing indicator; transaction and report date are the same.
Context
- These were merger-related dispositions (not routine open-market sales). Common shares/RSUs were surrendered to the issuer in connection with the Novartis acquisition; options were settled for cash (not exercised then held).
- Such M&A cash-outs are standard corporate action outcomes and do not necessarily signal the insider’s view on the company’s standalone near-term prospects.
Insider Transaction Report
Form 4Exit
Skerjanec Simona
Director
Transactions
- Disposition to Issuer
Common Stock
[F1]2026-02-27−6,692→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
[F2]2026-02-27−10,034→ 0 totalExercise: $33.62Exp: 2035-06-09→ Common Stock (10,034 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
[F2]2026-02-27−42,308→ 0 totalExercise: $28.91Exp: 2034-05-13→ Common Stock (42,308 underlying)
Footnotes (2)
- [F1]The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
- [F2]The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Signature
/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact|2026-02-27